Mpx (Monkeypox Virus)

Summary
Mpx is an acute viral disease characterized by painful papulopustular rash, swollen lymph nodes, and often fever, chills, myalgias, and headache. The rash may be located on hands, feet, chest, face, or mouth or near the genitals, including penis, testicles, labia, and vagina, and anus. The diagnosis should be confirmed by laboratory testing using polymerase chain reaction assay (PCR), Next-Generation sequencing of a clinical specimen, or isolation of mpx virus in culture from a clinical specimen.

Agent
Mpx virus is a double stranded DNA virus (monkeypox virus) that belongs to the genus orthopoxvirus, family poxviridae.

Transmission
Reservoir:
The exact reservoir is unknown, but it is likely that African rodents and primates might harbor the virus.

Mode of transmission:
- Direct contact with mpx lesions, saliva, or upper respiratory secretions of infected persons or animals. Mpx is usually transmitted through close, sustained physical contact and has been almost exclusively associated with sexual contact in the 2022 global outbreak. Fomite transmission can occur by touching objects, fabrics, and surfaces that have been used by someone with mpx and not disinfected, such as clothing, bedding, towels, fetish gear, or sex toys.

Period of communicability:
- 1-4 days before the onset of symptoms and/or rash until the rash has fully healed and a fresh layer of skin has formed. Illness typically lasts 2-4 weeks.

Clinical Disease
Incubation period:
Onset of prodromal symptoms typically occur within 3-17 days from exposure but can occur as late as 21 days from exposure.

Illness:
Mpx typically is a self-limiting disease with a characteristic rash that usually appears 3-17 after exposure. Along with the rash, other symptoms of mpx include fever, chills, swollen lymph nodes, fatigue, myalgias, headache, and respiratory symptoms (sore throat, nasal congestion, or cough). These symptoms can occur before rash but may occur after rash or not be present at all. The rash may be located on hands, feet, chest, face, or mouth or near the genitals, including penis, testicles, labia, and vagina, and anus. Rash lesions are firm or rubbery, well-circumscribed, deep-seated, and often develop umbilication (resembles a dot on the top of the lesion). The evolution of lesions progresses through four stages—macular, papular, vesicular, to pustular—before scabbing over and desquamation. Lesions have been described as painful.
until the healing phase when they become itchy. The risk of severe mpox infection is higher for persons with immunosuppressive conditions such as HIV or pregnancy. Complications include severe pain, ocular infections, myopericarditis, uncontrolled viral spread, neurologic complications, and complications associated with mucosal lesions.

**Laboratory Diagnosis**

Due to the rarity of smallpox and limited availability of mpox-specific tests, mpox can be diagnosed with either molecular or virologic testing for orthopoxvirus or monkeypox virus.

Virus can be isolated or detected by Orthopoxvirus DNA PCR or culture from swabs of skin lesion material, including skin lesion surface, exudate, or lesion crust. False positive PCR results are possible, and suspect cases with no risk factors (travel or recent new sexual partners) should be retested. False negative results are also possible when swabs are collected at the macule (early) or scab (late) stages. If clinically indicated, those tested at the early stage should be retested when lesions progress to papules.

**Treatment**

No specific antiviral therapy is available for mpox. However, Tecovirimat, which was developed to treat smallpox, can be used to treat mpox effectively because the viruses are so similar, but it is not FDA approved for this purpose. Tecovirimat is only prescribed to people with severe mpox disease such as persons with lesions on their eyes or genitalia, or who develop complications. Those who are at a high risk for severe mpox disease are also eligible to receive Tecovirimat including people with weakened immune systems. It is recommended for persons with severe mpox disease to receive hospital-based supportive care for complications or pain management.

**Surveillance**

**Case Definition (2023):**

**Suspect** –

- New characteristic rash\(^*\) OR
- Meets one of the epidemiologic criteria and has a high clinical suspicion\(†\) for mpox

**Probable** – No suspicion of other recent Orthopoxvirus exposure (e.g., Vaccinia virus in ACAM2000 vaccination) **AND** demonstration of the presence of

- Orthopoxvirus DNA by polymerase chain reaction of a clinical specimen OR
- Orthopoxvirus using immunohistochemical or electron microscopy testing methods OR
- Demonstration of detectable levels of anti-orthopoxvirus IgM antibody during the period of 4 to 56 days after rash onset

**Confirmed** –

- Demonstration of the presence of mpox virus DNA by polymerase chain reaction testing or Next-Generation sequencing of a clinical specimen **OR** isolation of mpox virus in culture from a clinical specimen
Epidemiologic Criteria – Within 21 days of illness onset:

- Reports having contact with a person or people with a similar appearing rash or who received a diagnosis of confirmed or probable mpox OR
- Had close or intimate in-person contact with individuals in a social network experiencing mpox activity, this includes men who have sex with men (MSM) who meet partners through an online website, digital application (“app”), or social event (e.g., a bar or party) OR
- Traveled outside the US to a country with confirmed cases of mpox or where mpox virus is endemic OR
- Had contact with a dead or live wild animal or exotic pet that is an African endemic species or used a product derived from such animals (e.g., game meat, creams, lotions, powders, etc.)

Exclusion Criteria – A case may be excluded as a suspect, probable, or confirmed case if:

- An alternative diagnosis* can fully explain the illness OR
- An individual with symptoms consistent with mpox does not develop a rash within 5 days of illness onset OR
- A case where high-quality specimens do not demonstrate the presence of Orthopoxvirus or mpox virus or antibodies to orthopoxvirus

†Clinical suspicion may exist if presentation is consistent with illnesses confused with mpox (e.g., secondary syphilis, herpes, and varicella zoster).

*The characteristic rash associated with mpox lesions involve the following: deep-seated and well-circumscribed lesions, often with central umbilication; and lesion progression through specific sequential stages—macules, papules, vesicles, pustules, and scabs.; this can sometimes be confused with other diseases that are more commonly encountered in clinical practice (e.g., secondary syphilis, herpes, and varicella zoster). Historically, sporadic accounts of patients co-infected with mpox virus and other infectious agents (e.g., varicella zoster, syphilis) have been reported, so patients with a characteristic rash should be considered for testing, even if other tests are positive.

Categorization may change as the investigation continues (e.g., a patient may go from suspect to probable).

Reporting:

Report all suspected, probable, or confirmed cases of mpox immediately (24/7/365) to the Epidemiology and Response Division (ERD) at 505-827-0006. Information needed includes: patient’s name, age, sex, race, ethnicity, home address, home phone number, occupation, and health care provider.
Case Investigation:

Complete the CDC Short Case Report Form and mail to the Epidemiology and Response Division, P.O. Box 26110, Santa Fe, New Mexico 87502-6110, or (preferably) fax to 505-827-0013. Investigation information should also be entered in NM-EDSS per established procedures.

**Control Measures**

1. **Case management**
   
   1.1. Isolation: People with mpox and symptomatic with fever or any respiratory symptoms (sore throat, nasal congestion, or cough) should be isolated at home and away from others (aside from medical visits) until fever and respiratory symptoms have resolved and mpox lesions have healed and a new layer of skin has formed. Wear a well-fitting mask and keep all lesions covered when around others. Avoid close contact with others and do not share linens, clothing, cups, eating utensils etc. Avoid contact with pets or other animals, minimize touching/petting.

   1.1.a In hospitals and institutions, patients should be placed in a single-person room with a dedicated bathroom with a door that can be kept closed. Special airborne precautions are not necessary. If the patient is transported outside of their room, they should use well-fitting source control (e.g., medical mask) and have any exposed skin lesions covered with a sheet or gown. Any procedures likely to spread oral secretions (e.g. Intubation or extubation) should be performed in an airborne infection isolation room.

2. **Contact management**

   2.1. Evidence of mpox vaccination:

   2.1.a Written documentation of mpox vaccination series: receipt of two doses of JYENNOS vaccine administered in or after 2022. Some adults may have received vaccination against smallpox as a child prior to 2022. People vaccinated during those years are not considered to have adequate immunization and the recommendation is for them to be re-vaccinated if eligible.

   2.1.b During a case investigation or outbreak, post-exposure prophylaxis should be considered for adults who had direct, skin-to-skin contact with index case during the infectious period. Prior vaccination, and how recently the exposed case completed their series, may impact the receipt of post-exposure prophylaxis in exposed contacts.

2.2. Isolation: Individuals exposed to mpox virus can continue their routine daily activities (e.g., go to work or school) if they do not have signs or symptoms consistent with mpox.

2.3. Post-Exposure Prophylaxis:

   2.3.a Smallpox vaccination (JYENNOS), if given within 4 days of mpox exposure, may prevent disease in susceptible persons. Post-exposure prophylaxis may be administered between 4-14 days after last exposure, but within 4 days is ideal.

3. **Prevention**

   3.1. Immunization:
3.1.a A single dose of JYENNOS vaccine reduced mpox occurrence by 37%, while two doses reduced mpox occurrence by 69% among vaccine eligible men aged 18-49. In the 2022 outbreak, mpox incidence was 14 times higher among unvaccinated persons compared to persons who had received at least one dose of JYENNOS. After vaccination, it is not known how long protection may last or if protection decreases over time. These data and analyses are forthcoming.

References


See Mpox Fact Sheets (English) (Spanish)